Drug injection stopper with thin film lubricant

Abstract

Syringe stoppers containing low levels (i.e., about 0.3 μg to about 100 μg) of thin film lubricant are provided. The stoppers may be positioned inside the barrel of a syringe or autoinjector. The stoppers include an elastomeric body, a solid lubricant, and a thin film lubricant. The amount of thin film lubricant present on the stoppers is below the level that would cause particle formation in a barrel without silicone. In addition, the low level of thin film lubricant allows for lower breakaway forces (both wet and dry), average sliding forces, and reduced glide forces compared to stoppers without thin film lubricant. The low amount of thin film lubricant present on the stoppers also reduces the average insertion force inside a syringe or vent tube compared to stoppers without thin film lubricant, which can improve machinability, including insertion.

Description

[Technical field]

[0001] The present disclosure relates generally to injection devices having low levels of lubrication. More specifically, the disclosure relates to injection devices having elastomeric stoppers with low levels of lubrication interacting with the surface of the stopper, and methods of making and using the injection devices. [Background technology]

[0002] Injection devices (e.g., syringes, autoinjectors) used for delivery of drugs include a barrel and a stopper. The stopper is slidably fitted inside the barrel, and a plunger rod may be fixed to the stopper for actuation of the syringe and delivery of the drug. A liquid lubricant (e.g., silicone oil) is often provided in the injection device to reduce sliding friction between the stopper and the barrel and improve the sealing action between them. Prefilled injection devices may be used as a method to both store and deliver drugs. However, the liquid lubricant present in the injection device may diffuse into the drug that may be contained in the injection device and injected into the patient. Silicone oil may be of particular concern with biopharmaceuticals, because it may cause aggregation of certain proteins, making the biopharmaceuticals unusable for injection. Summary of the Invention [Means for solving the problem]

[0003] According to one embodiment ("Embodiment 1"), a syringe includes a barrel configured to hold a therapeutic agent and a plunger rod positioned at least partially within the barrel. The plunger rod includes a stopper having an elastomeric body, a solid lubricant disposed on at least a portion of an exterior of the elastomeric body, and a thin film lubricant positioned between the solid lubricant and an interior of the barrel. The mass of the thin film lubricant on the stopper is about 0.3 μg to about 100 μg.

[0004] According to another embodiment ("embodiment 2") in addition to embodiment 1, the thin film lubricant is a silicone and the solid lubricant is a fluoropolymer.

[0005] According to another aspect ("Aspect 3") which is added to Aspect 1 or Aspect 2, the solid lubricant on the stopper and the thin film lubricant constitute the total lubricant in the syringe.

[0006] According to another aspect ("Aspect 4") that further adds to any one of Aspects 1 to 3, the stopper is configured to be slidably moved within the barrel with a dry breakaway force of less than about 15 N.

[0007] According to one embodiment ("Embodiment 5"), a syringe includes a barrel configured to hold a therapeutic agent and a plunger rod positioned at least partially within the barrel, the plunger rod including a stopper. The stopper includes an elastomeric body, a solid lubricant disposed on at least a portion of an exterior of the elastomeric body, and a thin film lubricant positioned between the solid lubricant and an interior of the barrel. The areal density of the thin film lubricant on the stopper is about 0.15 μg / cm 2 ~Approx. 50μg / cm 2 It is.

[0008] According to another embodiment ("embodiment 6") in addition to embodiment 5, the thin film lubricant is a silicone and the solid lubricant is a fluoropolymer.

[0009] According to another aspect ("Aspect 7") that is further added to Aspect 5 or Aspect 6, the thin film lubricant reduces an insertion force required to insert the stopper into the barrel by at least about 10%.

[0010] According to another embodiment ("Embodiment 8") that further adds to any one of embodiments 5 to 7, the thin film lubricant reduces a breakaway force required to move the stopper within the barrel by at least about 10%.

[0011] According to another embodiment ("Embodiment 9") that further adds to any one of embodiments 5 to 8, the thin film lubricant reduces an average glide force required to move the stopper within the barrel by at least about 2%.

[0012] According to another embodiment ("embodiment 10") that further adds to any one of embodiments 5 to 9, an average wet glide force between the stopper and the barrel is less than 5 N.

[0013] According to another embodiment ("embodiment 11") that is further added to any one of embodiments 5 to 10, the thin film lubricant is present in an amount of about 0.3 μg to about 50 μg by weight.

[0014] According to one embodiment ("Embodiment 12"), an injection device includes a barrel configured to hold a therapeutic agent and a plunger rod positioned at least partially within the barrel, the plunger rod including a stopper. The stopper includes an elastomeric body, a solid lubricant disposed on at least a portion of an exterior of the elastomeric body, and a thin film lubricant positioned between the solid lubricant and an interior of the barrel. The therapeutic agent has an average number of particles having a diameter of 10 μm or greater not greater than about 600, and an average number of particles having a diameter of 25 μm or greater not greater than about 60.

[0015] According to another embodiment ("embodiment 13") in addition to embodiment 12, the thin film lubricant is a silicone and the solid lubricant is a fluoropolymer.

[0016] According to another embodiment ("embodiment 14") which is added to embodiment 12 or embodiment 13, the amount of the thin film lubricant present on the stopper is about 0.3 μg to about 100 μg.

[0017] According to one embodiment ("Embodiment 15"), a method of inserting a stopper into a syringe includes the steps of lubricating at least one of the stopper, a vent tube, and a barrel with a thin film lubricant, compressing the stopper such that a diameter of the stopper is smaller than a diameter of the vent tube, inserting the stopper into the vent tube, positioning the vent tube at least partially within the barrel, and inserting the stopper into the barrel. The stopper contains about 0.3 μg to about 100 μg of thin film lubricant when inserted into the barrel.

[0018] According to another embodiment ("embodiment 16") in addition to embodiment 15, the thin film lubricant is a silicone.

[0019] According to another aspect ("Aspect 17") that further adds to Aspect 15 or Aspect 16, the lubrication step reduces the insertion force by at least about 5% during at least one of the insertion steps compared to a method without a lubrication step.

[0020] According to another embodiment ("Embodiment 18") of any one of embodiments 15 to 17, the method includes filling at least a portion of the barrel with a therapeutic agent, wherein the average number of particles present in the therapeutic agent is not more than about 600 particles having a diameter of 10 μm or greater and not more than about 60 particles having a diameter of 25 μm or greater.

[0021] According to another embodiment ("embodiment 19") of any one of embodiments 15 to 18, lubricating the stopper includes lubricating the stopper with the thin film lubricant. The thin film lubricant has a concentration of about 0.15 μg / cm 2 ~Approx. 50μg / cm 2 has a surface area density on said stopper of

[0022] According to another aspect ("Aspect 20") which is further added to any one of Aspects 15 to 19, an insertion force required to insert the stopper into the barrel is less than 30 N.

[0023] The preceding embodiments are merely examples and should not be read to limit or narrow the scope of any of the inventive concepts otherwise provided by this disclosure. Numerous examples are disclosed, and still other embodiments will become apparent to those skilled in the art from the following detailed description. The following detailed description illustrates and describes. Thus, the drawings and detailed description should be regarded as illustrative in nature and not as restrictive in nature.

[0024] The accompanying drawings are included to provide a further understanding of the disclosure, and are incorporated in and constitute a part of this specification, illustrating embodiments and, together with the description, serving to explain the principles of the disclosure. [Brief description of the drawings]

[0025] [Figure 1] FIG. 1 is a diagram showing a syringe according to one embodiment. [Diagram 2] FIG. 2 is a cutaway view showing the stopper inside the syringe of FIG. 1 according to one embodiment. [Diagram 3] FIG. 3 is a flow diagram illustrating a method for positioning a stopper within a syringe according to one embodiment. [Figure 4A] FIG. 4A is a plot showing force versus displacement data for multiple stopper samples in empty syringes according to Example 2. [Figure 4B] FIG. 4B is a plot showing force versus displacement data for multiple stopper samples in empty syringes according to Example 2. [Diagram 5] FIG. 5 is a plot showing removal force data for several stopper samples according to Example 2. [Figure 6A] FIG. 6A is a plot showing force versus displacement data for a non-lubricated stopper sample passing through a vent tube according to Example 3. [Figure 6B] FIG. 6B is a plot showing force versus displacement data for a lubricating thin film stopper sample passing through a vent tube according to Example 3. [Figure 7]FIG. 7 is a plot showing breakaway force data for multiple stopper-barrel systems according to Example 4. [Figure 8] FIG. 8 is a plot showing maximum glide force for a multiple stopper-barrel system according to Example 4. [Figure 9A] FIG. 9A is a plot showing force versus displacement data for several stopper samples in pre-filled syringes according to Example 4. [Figure 9B] FIG. 9B is a plot showing force versus displacement data for multiple stopper samples in pre-filled syringes according to Example 4. [Figure 9C] FIG. 9C is a plot showing force versus displacement data for several stopper samples in pre-filled syringes according to Example 4. [Figure 9D] FIG. 9D is a plot showing force versus displacement data for multiple stopper samples in pre-filled syringes according to Example 4. [Figure 9E] FIG. 9E is a plot showing force versus displacement data for multiple stopper samples in pre-filled syringes according to Example 4. [Figure 9F] FIG. 9F is a plot showing force versus displacement data for multiple stopper samples in pre-filled syringes according to Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] Definitions and Terminology This disclosure is not intended to be read in a restrictive manner, for example, the terms used in this application should be read broadly in light of the meaning that one of ordinary skill in the art would ascribe to such terms.

[0027] With respect to terms expressing imprecision, the terms "about" and "approximately" are used interchangeably. Measurements that are very close to a stated measurement deviate from the stated measurement by a fairly small amount that can be understood and easily ascertained by a person skilled in the art. Such deviations can be attributed, for example, to measurement errors, differences in measurement and / or manufacturing equipment calibration, human error in reading and / or setting measurements, performance and / or construction parameters that take into account differences in measurements relative to other components, fine-tuning made to optimize a particular implementation scenario, imprecise adjustment and / or manipulation of objects by humans or machines, and / or the like. In cases where it is determined that such fairly small differences are not easily ascertainable by a person skilled in the art, the terms "about" and "approximately" can be understood to mean plus or minus 10% of the stated value.

[0028] Description of Various Embodiments As will be apparent to one of ordinary skill in the art, the various aspects of the disclosure may be implemented by any number of methods and devices configured to perform the intended functions. It should be noted that the accompanying drawings referred to herein are not necessarily drawn to scale and may be exaggerated to illustrate the various aspects of the disclosure. In that regard, the drawings should not be construed as limiting.

[0029] I. Drug Injection Devices 1, an embodiment of a drug injection device (e.g., a syringe) 100 is provided for delivering at least one therapeutic agent 150 to a patient. Suitable therapeutic agents 150 include, but are not limited to, small molecule drugs, biologics, antibodies, antisense drugs, RNA interference drugs, gene therapy drugs, primary and embryonic stem cells, vaccines, and any bioactive compound, and combinations thereof. Other suitable drug injection devices within the scope of the present disclosure include, for example, an autoinjector.

[0030] 1 includes a barrel 110, sometimes referred to herein as a cartridge tube for ease of discussion, a plunger rod 120 having a stopper 200, and a piercing element (e.g., needle) 170, each of which is further described below. It is also within the scope of this disclosure for the syringe 100 to be a "needle-free" device having a Luer-Lok® system (not shown).

[0031] The barrel 110 of the syringe 100 contains the liquid therapeutic agent 150, a distal end 112 facing the patient, a proximal end 113 facing away from the patient, and an inner surface 115 facing inwardly toward the liquid therapeutic agent 150. The barrel 110 may be formed from a hard material, such as a glass material (borosilicate glass), a ceramic material, one or more polymeric materials (e.g., polypropylene, polyethylene, and copolymers thereof), a metal material, a plastic material (cyclic olefin polymers, and cyclic olefin copolymers), and combinations thereof. In some embodiments, the barrel 110 may be formed from glass, resin, plastic, or metal, with some amount of lubricant present on the inner surface 115 of the barrel 110. The barrel 110 may be supplied with a prefilled liquid therapeutic agent 150, or the therapeutic agent 150 may be drawn into the barrel 110 prior to use.

[0032] Movement of the stopper 200 toward the distal end 112 of the barrel 110 allows the plunger rod 120 of the syringe 100 to be moved within the barrel 110 to load and / or eject the therapeutic agent 150. The plunger rod 120 includes a head 122 extending from a proximal end 113 of the plunger rod 120. The stopper 200 is coupled to the opposite end of the plunger rod 120 at the distal end 114 of the plunger rod 120. Although the exemplary stopper 200 of FIG. 1 contacts the inner surface 115 of the barrel 110 via one or more sealing ribs 201, 202, any number of sealing and / or non-sealing ribs may be present on the stopper 200. As used herein, the term "sealing rib" means a rib of a stopper that contacts the inner surface 115 of the barrel 110 to prevent air or other contaminants from entering the barrel 110 or the therapeutic agent 150 from exiting the barrel 110. As used herein, a "non-sealing" rib means a rib that does not contact or that contacts the inner surface 115 of the barrel 110 such that air (or other contaminants) and / or therapeutic agent 150 may pass through.

[0033] As shown in FIG. 1 , the stopper 200 may be positioned at a predetermined location in the barrel 110 relative to the therapeutic agent 150. The therapeutic agent 150 has a liquid height H2. The liquid height H2 depends on the volume of the therapeutic agent 150 in the barrel 110. The stopper 200 may be positioned at a predetermined stopper height, or “headspace” H1 above the therapeutic agent 150. The headspace H1 may be measured from the top surface of the therapeutic agent 150 to the nearest sealing rib 201 of the stopper 200. The headspace H1 may be selected to control the amount of air in the barrel 110 between the stopper 200 and the therapeutic agent 150. In some embodiments, the headspace H1 is less than about 25 mm, less than about 23 mm, less than 21 mm, less than about 19 mm, less than about 17 mm, less than about 15 mm, less than about 13 mm, less than about 10 mm, less than about 8 mm, less than about 5 mm, less than about 3 mm, less than about 2 mm, less than about 1 mm, or less than about 0.5 mm. The headspace volume can be calculated by multiplying the headspace height H1 by the interior cross-sectional area of ​​the barrel 110, minus the volume of the stopper 200 that extends beyond the sealing rib 201 of the stopper 200 toward the therapeutic agent 150. In some embodiments, it can be advantageous to minimize the headspace H1 to reduce or avoid clumping of the therapeutic agent 150 within the syringe 100. The stopper 200 is described in more detail below in Section II.

[0034] The needle 170 of the syringe 100 shown in FIG. 1 may be coupled to the distal end 112 of the barrel 110. Of course, the depiction of the needle is representative in nature since the syringe 100 may be needleless and / or may not be coupled to a barrel, as is the case with self-injection devices. The needle 170 is configured to pierce the skin of a patient and inject the therapeutic agent 150 into the patient by depressing the head 122 of the plunger rod 120. If the needle 170 is removable, care should be taken to minimize bacterial contamination within the barrel 110 when coupling the needle 170 to the barrel 110 and / or when disengaging the needle 170 from the barrel 110. It is within the scope of this disclosure for the needle 170 to contain a lubricant for the comfort of the patient without affecting the lubricant exposed to the therapeutic agent 150 in the syringe 100.

[0035] II. Stopper 2, stopper 200 is shown in more detail, including an elastomeric body 210, a solid lubricant 220 disposed on at least a portion of an exterior surface of elastomeric body 210, and a thin film lubricant 230 disposed between solid lubricant 220 and inner surface 115 of barrel 110. Stopper 200 should have low air and liquid permeability to minimize leakage inside barrel 110 (FIG. 1) and introduction of air between stopper 200 and inner surface 115 of barrel 110 (FIG. 1) during loading and / or ejection of therapeutic agent 150. In this manner, stopper 200 can resist bacterial contamination within barrel 110. Stopper 200 should also have low friction slidability relative to barrel 110 to facilitate loading and / or ejection of therapeutic agent 150 within barrel 110, as described in more detail below.

[0036] The elastomeric body 210 of the stopper 200 may comprise any elastomer suitable for the application, such as butyl, halobutyl, bromobutyl, and / or chlorobutyl rubber, silicone, nitrile, styrene butadiene, polychloropropene, ethylene propylene diene, fluoroelastomer, thermoplastic elastomer (TPE), thermoplastic vulcanizate (TPV), or blends and / or copolymers of any of the foregoing, as would be readily identified by one of ordinary skill in the art. In other embodiments, the stopper 200 may be comprised of non-elastomeric materials, such as plastics (e.g., polypropylene, polycarbonate, and polyethylene), thermoplastics, or fluoropolymer materials, such as ethylene-(perfluoro-ethylene-propene) copolymer (EFEP), polyvinylidene fluoride (PVDF), and perfluoroalkoxy polymer resins (PFA).

[0037] The solid lubricant 220 of the stopper 200 may also be referred to herein as a coating, a polymer layer, a laminate layer, or a porous layer, and is configured to at least partially cover the elastomeric body 210. In some embodiments, the solid lubricant 220 may be a single layer of a polymer or an expanded polymer, or the solid lubricant 220 may be a multi-layer structure. The solid lubricant 220 may include a dense inner layer or an open microstructured inner layer to facilitate interaction with the underlying elastomeric body 210, such as receiving the elastomeric body 210 within the pores (not shown) of the solid lubricant 220. Similarly, the solid lubricant 220 may also include a dense outer layer or an open microstructured outer layer to facilitate interaction between the solid lubricant 220 and the thin film lubricant 230, such as receiving the thin film lubricant 230 within the pores (not shown) of the solid lubricant 220. Pores may be defined as the spaces between the nodes and fibrils within the microstructure of the solid lubricant 220.

[0038] The solid lubricant 220 may be comprised of a fluoropolymer, including, for example, polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), densified ePTFE, and copolymers and combinations thereof. Other potential fluoropolymers for use as the solid lubricant 220 include, for example, fluorinated ethylene propylene (FEP), ethylene tetrafluoroethylene (ETFE), polyvinyl fluoride, polyvinylidene fluoride (e.g., poly(vinylidene fluoride-co-tetrafluoroethylene) (VDF-co-TFE), poly(vinylidene fluoride-co-tetrafluoroethylene) (VDF-co-TrFE)), perfluoropropyl vinyl ether, perfluoroalkoxy polymers, and copolymers and combinations thereof. Yet another potential polymer for use as the solid lubricant 220 includes polyethylene (e.g., expanded ultra-high molecular weight polyethylene (eUHMWPE), e.g., as described in U.S. Pat. No. 9,926,416 to Sbriglia).

[0039] The thickness of the solid lubricant 220 may be less than about 30 microns, less than about 25 microns, less than about 20 microns, less than about 15 microns, less than about 10 microns, or about 5 microns. In some embodiments, the thickness of the solid lubricant 220 may be from about 0.5 microns to about 20 microns, from about 1 micron to about 15 microns, from about 1 micron to about 10 microns, from about 5 microns to about 10 microns, from about 1 micron to about 5 microns, or from about 7 microns to about 15 microns. The solid lubricant 220 and / or the elastomeric body 210 may be pre-treated or post-treated by chemical etching, plasma treatment, corona treatment, roughening, or the like to improve the affinity and bonding of the solid lubricant 220 to the elastomeric body 210 and / or the thin film lubricant 230 to the solid lubricant 220.

[0040] The thin film lubricant 230 of the stopper 200 is configured to be positioned between the solid lubricant 220 and the inner surface 115 of the barrel 110 and to further reduce friction between the stopper 200 and the barrel 110. In some embodiments, the thin film lubricant 230 is provided at a level sufficient to reduce friction within the syringe 100 while minimizing the amount of the thin film lubricant 230 that can diffuse into the therapeutic agent 150 and while maintaining a relatively reliable seal between the stopper 200 and the inner surface 115 of the barrel 110. The thin film lubricant 230 may interact with the solid lubricant 220 via chemical and / or physical features of the solid lubricant 220 to help the solid lubricant 220 retain the thin film lubricant 230 on the stopper 200 instead of diffusing into the therapeutic agent 150. For example, the thin film lubricant 230 may be incorporated onto the nodes and / or fibrils of the solid lubricant 220 and / or into the pores (not shown). Although the thin film lubricant 230 is shown in FIG. 2 as a continuous coating layer, it is within the scope of this disclosure for the thin film lubricant 230 to cover only discontinuous areas of the solid lubricant 220 .

[0041] In at least one embodiment, the thin film lubricant 230 is coated directly onto the solid lubricant 220 of the stopper 200 by spray application or by contacting the stopper 200 with another substrate (e.g., a coating tube) containing a predetermined amount of the thin film lubricant 230. The thin film lubricant 230 may be baked or crosslinked onto the solid lubricant 220 of the stopper 200. Depositing the thin film lubricant 230 directly onto the solid lubricant 220 of the stopper 200 may help prevent the thin film lubricant 230 from diffusing into the therapeutic agent 150. As described further herein, the thin film lubricant 230 may be applied to the solid lubricant 220 of the stopper 200 through a vent or insertion tube (not shown) or through the barrel 110. In some embodiments, the thin film lubricant 230 may be applied directly to the barrel 110. Additionally, the overall amount of thin film lubricant 230 in the system can be reduced by applying thin film lubricant 230 to a limited number of portions of barrel 110. In one embodiment, thin film lubricant 230 may be applied only to an upper portion of barrel 110 that comes into contact with stopper 200 in the unused configuration, and thin film lubricant 230 may be absent from a lower portion of barrel 110 that comes into contact with therapeutic agent 150 and stopper 200 in the used configuration.

[0042] Thin film lubricant 230 can be any solid or liquid lubricant. In some embodiments, thin film lubricant 230 is a silicone oil. In other embodiments, thin film lubricant 230 can be another lubricant, such as a polysorbate. Additionally, thin film lubricant 230 can be chemically or physically modified to improve its affinity for solid lubricant 220, thereby reducing the amount of thin film lubricant 230 that can be removed from stopper 200. In some embodiments, the thin film lubricant is formulated to have a higher affinity for solid lubricant 220 than for barrel 110 and / or therapeutic agent 150.

[0043] The amount of thin film lubricant 230 applied to the stopper 200 may vary widely. In at least one embodiment, the thin film lubricant 230 is applied at a "low" level, which may range from about 0.3 μg to about 100 μg per stopper 200. The amount of thin film lubricant 230 applied to the stopper 200 may range from about 0.3 μg to about 100 μg per stopper 200. It may be about 0.3 μg to about 100 μg, about 5 μg to about 100 μg, about 0.3 μg to about 90 μg, about 5 μg to about 90 μg, about 0.3 μg to about 80 μg, about 5 μg to about 80 μg, about 0.3 μg to about 70 μg, about 5 μg to about 70 μg, about 0.3 μg to about 60 μg, about 5 μg to about 60 μg, about 0.3 μg to about 50 μg, about 5 μg to about 50 μg, about 0.3 μg to about 40 μg, about 5 μg to about 40 μg, about 0.3 μg to about 30 μg, about 5 μg to about 30 μg, about 0.3 μg to about 20 μg, about 5 μg to about 20 μg, about 0.3 μg to about 10 μg, or about 5 μg to about 10 μg. Surface area is 2cm 2 For a surface density of a 1 mL stopper 200 of about 0.15 μg / cm 2 ~Approx. 50μg / cm 2 , about 2.5μg / cm 2 ~Approx. 50μg / cm 2 , about 0.15μg / cm 2 ~about 45μg / cm 2 , about 2.5μg / cm 2 ~about 45μg / cm 2 , about 0.15μg / cm 2 ~about 40μg / cm 2 , about 2.5μg / cm 2 ~about 40μg / cm 2 , about 0.15μg / cm 2 ~Approx. 35μg / cm 2 , about 2.5μg / cm 2 ~Approx. 35μg / cm 2 , about 0.15μg / cm 2 ~Approx. 30μg / cm 2 , about 2.5μg / cm 2 ~Approx. 30μg / cm 2 , about 0.15μg / cm 2 ~Approx. 25μg / cm 2 , about 2.5μg / cm 2 ~Approx. 25μg / cm 2 , about 0.15μg / cm2 ~about 20μg / cm 2 , about 2.5μg / cm 2 ~about 20μg / cm 2 , about 0.15μg / cm 2 ~Approx. 15μg / cm 2 , about 2.5μg / cm 2 ~Approx. 15μg / cm 2 , about 0.15μg / cm 2 ~about 10μg / cm 2 , about 2.5μg / cm 2 ~about 10μg / cm 2 , about 0.15μg / cm 2 ~Approx. 5μg / cm 2 , about 2.5μg / cm 2 ~Approx. 5μg / cm 2 may be present on the stopper 200 in an amount of 0.01 to 0.05 μm. Of course, the areal density may vary based on the size of the stopper 200.

[0044] The small amount of thin film lubricant 230 applied to the solid lubricant 220 of the stopper 200 and the interaction of the thin film lubricant 230 with the solid lubricant 220 prevents particles of the thin film lubricant 230 from entering the therapeutic agent 150 when the syringe 100 is stored or in use. This "small" amount of thin film lubricant 230 can be measured using gas chromatography (GC) mass spectrometry, inductively coupled plasma (ICP) mass spectrometry, and / or by the amount of particles present in the barrel 110 measured in water for injection (WFI) after WFI is exposed to the fully assembled syringe 100 (e.g., glass barrel 110, stopper 220, and at least one therapeutic agent 150). For example, the average number of particles present in the therapeutic agent 150 should not exceed about 600 particles / mL for diameters greater than 10 μm and should not exceed about 60 particles / mL for diameters greater than 25 μm.

[0045] The stopper 200 may be coated with a low level of thin film lubricant 230 as described above, which reduces or minimizes the amount of thin film lubricant 230 that diffuses into the therapeutic agent 150 inside the syringe 100 or otherwise separates from the stopper 200. The interaction of the thin film lubricant 230 with the solid lubricant 220 also helps to retain the thin film lubricant 230 on the stopper 200.

[0046] The thin film lubricant 230 allows for a lower average insertion force of the stopper 200 into the barrel 110 compared to a stopper without the thin film lubricant. In some embodiments, the presence of the thin film lubricant 230 may reduce the average insertion force by about 10%, about 15%, about 20%, about 25%, about 30%, or more compared to a stopper without the thin film lubricant. In some embodiments, the insertion force (i.e., the force required to insert the stopper into the barrel) may be less than 35N, less than 30N, less than 25N, less than 20N, or may fall within any range including any two of these values ​​as endpoints. In at least one embodiment, the insertion force to insert the stopper 200 into the barrel 110 through the vent tube may be about 20N to about 30N for a 1 mL syringe 100.

[0047] The thin film lubricant 230 allows for a lower breakaway force of the stopper within the barrel 110 compared to a stopper without the thin film lubricant. In certain embodiments, the presence of the thin film lubricant 230 may reduce the breakaway force (wet or dry) by about 10%, about 15%, about 20%, about 25%, or more compared to a stopper without the thin film lubricant. In some embodiments, the dry breakaway force between the stopper 200 and the barrel 110 (i.e., the force required to initially move the stopper within the barrel with no liquid in the barrel) may be less than about 15 N, less than about 12.5 N, less than about 10 N, less than about 7.5 N, or less than about 5 N. In some embodiments, the dry breakaway force between the stopper 200 and the barrel 110 may be about 8 N to about 12 N for a 1 mL syringe 100. Further, in some embodiments, the wet break-off force (i.e., the force required to initially move the stopper within the barrel with liquid in the barrel) may be less than about 15 N, less than about 10 N, less than about 7.5 N, less than about 5 N, or within any range including any two of these values ​​as endpoints. In at least one embodiment, the wet break-off force between the stopper 200 and the barrel 110 may be between about 7 N and about 10 N.

[0048] The table below shows estimated wet and dry average breakaway force values ​​of a stopper without a thin film lubricant ("No Lubricant") compared to an otherwise identical stopper 200 with a thin film lubricant 230 described herein ("Low Lubricant"). [Table 1]

[0049] The thin film lubricant 230 also enables a lower average glide force of the stopper 200 within the barrel 110 as compared to a comparable stopper without the thin film lubricant. In some embodiments, the presence of the thin film lubricant 230 may reduce the average sliding force by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, or more as compared to a stopper without the thin film lubricant 230. In some embodiments, the disclosed stoppers 200 may exhibit comparable glide forces as compared to stoppers without the thin film lubricant, but may reduce insertion and / or removal forces.

[0050] In some embodiments, the wet maximum glide force (i.e., the maximum force required to move the stopper when liquid is present in the barrel and the stopper begins to move within the barrel) and / or the wet average glide force (i.e., the average force required to move the stopper when liquid is present in the barrel and the stopper begins to move within the barrel) may be less than 10 N, less than 9 N, less than 8 N, less than 7 N, less than 6 N, less than 5 N, less than 4 N, less than 3 N, or within any range including any two of these values ​​as endpoints. For example, the wet average glide force between the stopper 200 and the barrel 110 may be about 3 N to about 5 N for a 1 mL syringe 100. The wet maximum glide force between the stopper 200 and the barrel 110 may be about 5 N to about 8 N for a 1 mL syringe 100.

[0051] Additionally, the stopper 200 may exhibit improved or equivalent sealing between the stopper 200 and the inner surface 115 of the barrel 110 as compared to a stopper without a thin film lubricant. In some embodiments, this sealing may be evaluated using a container integrity test method, as further described below.

[0052] III. Assemblage method 3, a method 300 of inserting a stopper 200 into a barrel 110 is shown. The method 300 includes a compression step 305 involving compressing the stopper, a first insertion step 310 involving inserting the stopper 200 into a vent tube or insertion tube (not shown), a positioning step 315 involving positioning the vent tube within the barrel 110, and a second insertion step 320 involving inserting the stopper 200 into the barrel 110. The method 300 also includes one or more lubrication steps. These lubrication steps include a lubrication step 302 involving lubricating the stopper 200 with a thin film lubricant 230, a lubrication step 303 involving lubricating the vent tube with a thin film lubricant 230, and / or a lubrication step 304 involving lubricating the barrel 110 with a thin film lubricant 230. The stopper 200 is first compressed so that it fits inside the vent tube during the compression step 305. The stopper 200 may optionally be lubricated during the lubrication step 302 or coated with a thin film lubricant 230 prior to the compression step 305 .

[0053] The compressed stopper 200 may then be inserted into the vent tube during a first insertion step 310. The diameter of the vent tube is smaller than the inner diameter D1 (see FIG. 1 ) of the barrel 110. Before the stopper 200 is inserted into the vent tube during the first insertion step 310, the vent tube may optionally be lubricated with thin film lubricant 230 during a lubrication step 303. In embodiments in which the vent tube is lubricated with thin film lubricant 230, the stopper 200 may not be lubricated before insertion into the vent tube and may be coated with thin film lubricant 230 by contacting the thin film lubricant 230 on the inner surface of the vent tube. Once the stopper 200 is inserted into the vent tube, the vent tube is then positioned inside the barrel 110 during a positioning step 315. Instead of or in addition to lubricating the stopper 200 during lubrication step 302 and / or lubricating the vent tube during lubrication step 303, the inside of the barrel 110 may optionally be lubricated with a thin film lubricant 230 during lubrication step 304. The stopper 200 may then be inserted into the barrel 110 during a second insertion step 320. Moving the stopper 200 from the vent tube into the barrel 110 may be accomplished by using an insertion rod. Further examples of insertion systems and methods are disclosed in WO 2020 / 112612 to WL Gore & Associates. In some embodiments, the stopper 200 may be inserted into the barrel 110 via vacuum insertion, with a vent tube, or a combination thereof.

[0054] As will be apparent to one of ordinary skill in the art, the various aspects of the disclosure may be implemented by any number of methods and devices configured to perform the intended functions. It should be noted that the accompanying drawings referred to herein are not necessarily drawn to scale and may be exaggerated to illustrate the various aspects of the disclosure. In that regard, the drawings should not be construed as limiting.

[0055] The syringe and stopper shown in Figures 1 and 2 are provided as examples of various embodiments of a syringe. Combinations of the illustrated embodiments are clearly within the scope of the invention, but the examples and their description are not intended to suggest that the inventive concepts provided herein are limited to fewer, additional, or alternative embodiments to one or more of those embodiments shown in Figures 1 and 2.

[0056] Test Method It will be appreciated that although certain methods and equipment are described below, other methods or equipment may be substituted as deemed suitable by those skilled in the art.

[0057] Quantification of lubricants (silicones) To determine the amount of silicone present on the stoppers, the stoppers were extracted with a suitable organic solvent, in this case n-heptane (i.e., reflux extraction at elevated temperature or sonication). Total extractable silicone was then determined by graphite furnace atomic absorption spectrometry (GF-AAS) using the standard addition method. Organically soluble silicon (Si) was measured by GF-AAS and calculated as polydimethylsiloxane (PDMS) with a Si content of 38 wt%. Data from multiple stoppers was averaged for each type of stopper tested.

[0058] Insertion force method The insertion force was measured on an Instron UTM (compression test, preload 0.02N at 20mm / min, test speed 40mm / s, test reference end 70N, data acquisition speed 1ms). Six of each plunger type were tested for insertion force by insertion into the barrel through the vent tube.

[0059] Break-off and sliding friction test The breakaway and average sliding forces were measured by inserting the stoppers into an empty syringe (for "dry" measurements) or into a syringe filled with 0.96 mL of water for injection (WFI) (for "wet" measurements) using a vented tube stopper insertion machine. The syringes used were of a staked needle design with a 29 gauge ½ inch needle. A plunger rod suitable to mate with the stopper was fitted into the assembled syringe system without moving or disturbing the stopper. The system was placed into a holder on the force-displacement analyzer and a test speed of 250 mm / min was established. Force-displacement data was then acquired. The maximum force obtained was recorded. The force-displacement instrument used was a TA XT Plus Texture Analyzer (Hamilton, MA) or a Zwick UTM with a TA 270N syringe test fixture.

[0060] Container Integrity Testing Each syringe was filled to nominal with WFI. The WFI in the syringe did not contain any traces of blue (solution or colorant). The stopper to be tested was fitted into the syringe. The syringe was then immersed in a solution of 0.1% (1 g per liter) methylene blue and the external pressure was reduced to 27 kPa for 10 minutes using a Haug Pack Vac chamber / system according to USP 1207. The pressure was then returned to atmospheric pressure and the syringe was left immersed for 30 minutes. The outside of the vial was then rinsed. If the syringe did not contain any traces of blue solution, the stopper was considered to have passed the test.

[0061] Characterization of subvisible particles The silicone-containing subvisible particles were characterized via microfluidic imaging (MFI). A syringe barrel was filled with WFI and a stopper was inserted as described above. The sample was inverted 20 times and the released WFI was analyzed using a FlowCAM VS-1 microfluidic imaging machine with a 10X objective, a 10X choriometer, and a FC100x2 100 μm flow cell corresponding to 10X. EXAMPLES

[0062] Example 1: Preparation of stoppers 1 mL long syringe stoppers were used for all of the following examples. Each stopper was tested using silicone oil as a thin film lubricant. The stoppers tested were classified as follows: Control 1 and Control 2 stoppers had no silicone added, but traces of silicone were found on the Control 2 stopper, as shown in Table 2 below. The "SA" stopper was coated with a thin film of silicone by contacting the stopper with other silicone coated stoppers and agitating the stopper. The "SV" stopper was coated with a thin film of silicone by lubricating the vent tube that was inserted into each barrel along with the stopper. Both the SA and SV stoppers were inserted with a vent tube from Supplier 1, but the SV vent tube was treated with a trace of silicone prior to insertion. The "SVT" stopper was lubricated with silicone like the SV, but used a vent tube from Supplier 2. The stainless steel tubes from both suppliers were prepared generally according to the teachings of LaRose, U.S. Patent No. 10,369,292. The amount of silicone present in each of the stoppers was determined using the procedure described above and the results are shown below in Table 2. The limits of quantification for this procedure were 0.6 μg / stopper for Control 1 and 1.3 μg / stopper for the remainder of the stoppers, and the uncertainty was calculated with k=2.

[0063] [Table 2]

[0064] Because the procedure for determining the amount of silicone on a stopper is destructive, the same stopper used in determining the amount of silicone present was not used for the following example test.Instead, a similar stopper was used that was prepared by the same method and therefore should contain similar silicone levels.The control stopper used in the following examples is closest to Control 2 and may be referred to simply as "Control" below.

[0065] Example 2: Container Integrity and Dry Slide Performance Twenty syringes incorporating stoppers with a thin film lubricant were tested for container integrity. None of the samples showed evidence of blue dye ingress.

[0066] Referring now to Figure 4, the force-displacement data for each stopper sample inserted into an empty bare glass syringe barrel (wherein there was no solid or liquid lubricant) is plotted. From this data, the breakaway force and average glide force were determined. As shown, the stoppers coated with the thin film lubricant exhibited a more consistent sliding force profile compared to the unlubricated control.

[0067] Referring now to Figure 5, the dry break-off force for each stopper sample is plotted. As shown, each of the stoppers coated with the thin film lubricant exhibited significantly lower dry break-off forces when compared to the unlubricated control. Such a reduction indicates that while lower levels of silicone are present on the stoppers, the thin film lubricant still provides a benefit to the force required to initiate and continue movement of the stopper.

[0068] Example 3: Insertion Force For this example, stoppers with and without thin film lubricant (i.e., silicone oil) were inserted into the barrel through the vent tube and the insertion force was measured. The stoppers tested were GORE ImproJect 1 mL Long. Stopper samples with low silicone levels from the presence of thin film lubricant were prepared by placing the stoppers (n=108) into a small container and adding 1 μL of Dow Corning 360 silicone oil into the container. The container was tumbled until all stoppers were evenly coated. A "generic" stopper (available from West FluroTec®) was used for testing purposes as a comparative example. However, the generic stopper exceeded the maximum insertion force of the instrument and could not be inserted into the barrel using the same vent tube (having the same vent tube geometry). The results are summarized in Table 3 below and the corresponding force-displacement data through the vent tube is shown in Figure 6.

[0069] [Table 3]

[0070] As shown in Table 3 above, the addition of a thin film lubricant significantly reduces the insertion force required to insert the stopper along with the vent tube into the barrel.

[0071] Example 4: Wet Break-Off and Glide Force Test In this example, multiple stoppers and barrels were tested for withdrawal and glide forces. The stoppers were either non-lubricated stoppers, stoppers lubricated with a thin film lubricant, or "generic" stoppers (non-lubricated or lubricated plungers were GORE ImproJect 1 mL long. Generic plungers were West FluroTec® with a B2 coating). The stoppers were inserted into either non-lubricated or lubricated barrels (barrels were Schott 1 mL long barrels siliconized by using a ZebraSci Flex FP spray system and Dow Corning 360 silicone oil). The stopper-barrel systems were labeled as shown in Table 4 below. The thin film lubricant applied was silicone oil, and therefore the stoppers and / or barrels containing the thin film lubricant may hereafter be referred to as "siliconized."

[0072] [Table 4]

[0073] Samples for break-off force (or break loose force) and glide force testing were prepared using a manual vent tube insertion fixture for the Gore stoppers and a Groninger Mechanical stoppering machine for the West Fluorotec stoppers. Each sample was filled with 1 mL of water for injection (WFI). Six individual configurations (A-F) were tested for wet break-off force and glide force.

[0074] The wet break-off force data is summarized in Figure 7 and Table 5 below. The wet glide force data is summarized in Figure 8 and Tables 6 and 7 below. Figure 8 and Table 6 show the maximum glide force, while Table 7 shows the average glide force. Figure 9 shows the corresponding sliding curves for each sample group.

[0075] [Table 5]

[0076] [Table 6]

[0077] [Table 7]

[0078] As shown in Figures 7-9 and Tables 5-7, application of a thin film lubricant (e.g., silicone oil) significantly reduced the breakaway and glide forces of the stopper-barrel system. With respect to breakaway force, the non-silicone treated barrel with the non-silicone treated stopper had the highest average breakaway force, followed by the non-silicone treated barrel with the low siliconized stopper, and then the non-silicone treated barrel with the generic plunger. With respect to glide force, the highest glide force was observed in the non-silicone treated barrel with the generic stopper, and then the low siliconized barrel with the generic stopper. The non-silicone treated barrel and the non-silicone treated stopper exhibited the second highest maximum glide force compared to the remaining samples. Application of a "low" level of thin film lubricant reduced breakaway and / or glide force while minimizing the amount of lubricant in the system.

[0079] Example 5 - Silicone Quantification of Examples 3 and 4 The amount of silicone present in each of the stoppers and barrels in Examples 3 and 4 was determined using the procedures described above, and the results were calculated and are shown respectively in Tables 8 and 9. The limits of silicone quantification for this example were 0.3 μg / stopper and 0.5 μg / barrel.

[0080] [Table 8]

[0081] [Table 9]

[0082] Example 6 - Characterization of sub-visible particles Syringes incorporating stoppers with thin film lubricant (Sample B) were tested for particles by MFI as described above. The results shown in Table 10 are the average of three replicate runs. Silicone particles were identified via image analysis.

[0083] [Table 10]

[0084] The invention of this application has been described generally and in relation to specific embodiments as above. As will be apparent to those skilled in the art, various modifications and changes can be made in the embodiments without departing from the scope of the disclosure. Therefore, it is intended that these embodiments cover the modifications and changes of the present invention provided they fall within the scope of the appended claims and their equivalents. The aspects of the present invention are listed below. (Aspect 1) a barrel configured to hold a therapeutic agent; a plunger rod positioned at least partially within the barrel; 1. A syringe comprising: The plunger rod includes a stopper. The stopper is An elastomer body; a solid lubricant disposed on at least a portion of the exterior of the elastomeric body; a thin film lubricant positioned between the solid lubricant and the inside of the barrel; and wherein the mass of the thin film lubricant on the stopper is about 0.3 μg to about 100 μg. (Aspect 2) 2. The syringe of embodiment 1, wherein the thin film lubricant is a silicone and the solid lubricant is a fluoropolymer. (Aspect 3) 3. The syringe of claim 1 or 2, wherein the solid lubricant on the stopper and the thin film lubricant constitute the total lubricant in the syringe. (Aspect 4) A syringe according to any one of aspects 1 to 3, wherein the stopper is configured to be slidably moved within the barrel with a dry breakaway force of less than about 15 N. (Aspect 5) a barrel configured to hold a therapeutic agent; a plunger rod positioned at least partially within the barrel; 1. A syringe comprising: The plunger rod includes a stopper. The stopper is An elastomer body; a solid lubricant disposed on at least a portion of the exterior of the elastomeric body; a thin film lubricant positioned between the solid lubricant and the inside of the barrel; and the areal density of the thin film lubricant on the stopper is about 0.15 μg / cm 2 ~Approx. 50μg / cm 2 A syringe comprising: (Aspect 6) 6. The syringe of embodiment 5, wherein the thin film lubricant is a silicone and the solid lubricant is a fluoropolymer. (Aspect 7) 7. The syringe of claim 5 or 6, wherein the thin film lubricant reduces the insertion force required to insert the stopper into the barrel by at least about 10%. (Aspect 8) The syringe of any one of aspects 5-7, wherein the thin film lubricant reduces the breakaway force required to move the stopper within the barrel by at least about 10%. (Aspect 9) The syringe of any one of aspects 5-8, wherein the thin film lubricant reduces the average glide force required to move the stopper within the barrel by at least about 2%. (Aspect 10) The syringe of any one of aspects 5 to 8, wherein the average wet glide force between the stopper and the barrel is less than 5 N. (Aspect 11) 10. The syringe of any one of aspects 5 to 9, wherein the thin film lubricant is present in an amount of about 0.3 μg to about 50 μg by mass. (Aspect 12) a barrel configured to hold a therapeutic agent; a plunger rod positioned at least partially within the barrel; 1. An injection device comprising: The plunger rod includes a stopper. The stopper is An elastomer body; a solid lubricant disposed on at least a portion of the exterior of the elastomeric body; a thin film lubricant positioned between the solid lubricant and the inside of the barrel; and An injection device, wherein the average number of particles present in said therapeutic agent that are 10 μm or larger in diameter is about 600 or less, and the average number of particles present in said therapeutic agent that are 25 μm or larger in diameter is about 60 or less. (Aspect 13) 13. An injection device according to embodiment 12, wherein the thin film lubricant is a silicone and the solid lubricant is a fluoropolymer. (Aspect 14) 14. The injection device according to claim 12 or 13, wherein the amount of the thin film lubricant present on the stopper is from about 0.3 μg to about 100 μg. (Aspect 15) 1. A method of inserting a stopper into a syringe, comprising: lubricating at least one of the stopper, the vent tube, and the barrel with a thin film lubricant; compressing the stopper so that the diameter of the stopper is smaller than the diameter of the vent pipe; Inserting the stopper into the vent pipe; positioning the vent tube at least partially within the barrel; and inserting the stopper into the barrel; The method of inserting a stopper into a syringe, wherein the stopper contains about 0.3 μg to about 100 μg of thin film lubricant when inserted into the barrel. (Aspect 16) 16. The method of embodiment 15, wherein the thin film lubricant is a silicone. (Aspect 17) 17. The method of any one of aspects 15 to 16, wherein the lubrication step reduces insertion force during at least one of the insertion steps by at least about 5% compared to a method without a lubrication step. (Aspect 18) 18. The method of any one of aspects 15-17, comprising filling at least a portion of the barrel with a therapeutic agent, wherein the average number of particles present in the therapeutic agent does not exceed about 600 particles having a diameter of 10 μm or greater and does not exceed about 60 particles having a diameter of 25 μm or greater. (Aspect 19) The lubricating step includes lubricating the stopper with the thin film lubricant, the thin film lubricant having a thickness of about 0.15 μg / cm 2 ~Approx. 50μg / cm 2 19. The method according to any one of aspects 15 to 18, wherein the stopper has a surface area density of (Aspect 20) 20. The method according to any one of aspects 15 to 19, wherein the step of inserting the stopper into the barrel requires an insertion force of less than 30 N.

Claims

1. a non-siliconized barrel configured to hold a therapeutic agent; and a plunger rod positioned at least partially within the barrel; 1. A syringe comprising: The plunger rod includes a stopper. The stopper is An elastomer body; a solid lubricant disposed on at least a portion of the exterior of the elastomeric body; a thin film lubricant applied to the solid lubricant and positioned between the solid lubricant and the inside of the barrel; and the mass of the thin film lubricant on the stopper is 0.3 μg to 100 μg; the barrel being selected from a glass material, a ceramic material, a polymeric material, a metallic material, or a plastic material; the thin film lubricant is a silicone or a silicone oil; the solid lubricant is selected from polytetrafluoroethylene, expanded polytetrafluoroethylene, or polyethylene; and The solid lubricant on the stopper and the thin film lubricant constitute the total lubricant in the syringe. A syringe comprising:

2. 10. The syringe of claim 1, wherein the stopper is configured to be slidably moved within the barrel with a dry breakaway force of less than 15 N.

3. a non-siliconized barrel configured to hold a therapeutic agent; and a plunger rod positioned at least partially within the barrel; 1. An injection device comprising: The plunger rod includes a stopper. The stopper is An elastomer body; a solid lubricant disposed on at least a portion of the exterior of the elastomeric body; a thin film lubricant applied to the stopper and positioned between the solid lubricant and the inside of the barrel; and the average number of particles in said therapeutic agent that are 10 μm or greater in diameter is 600 or less, and the average number of particles in said therapeutic agent that are 25 μm or greater in diameter is 60 or less; the thin film lubricant is a silicone or a silicone oil; the mass of the thin film lubricant on the stopper is between 0.3 μg and 100 μg; the barrel being selected from a glass material, a ceramic material, a polymeric material, a metallic material, or a plastic material; the solid lubricant is selected from polytetrafluoroethylene, expanded polytetrafluoroethylene, or polyethylene; and The solid lubricant on the stopper and the thin film lubricant constitute the total lubricant in the syringe. An injection device comprising:

Images